Dianthus Therapeutics (DNTH)
108.10
+0.25 (0.23%)
Upcoming Events
Latest Headlines
Citi initiates Dianthus Therapeutics coverage with Buy rating
September 4, 2026 5:09 AM - StreetInsider
This biotech stock still Wolfe's top pick as multiple catalysts loomh
August 31, 2026 8:00 AM - StreetInsider
Form 4 Dianthus Therapeutics, For: Aug 19 Filed by: Read Simon
August 19, 2026 6:03 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Aug 13 Filed by: Veness Adam M
August 14, 2026 4:33 PM - SEC Filing
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Sirenia Capital Management LP
August 14, 2026 8:33 AM - SEC Filing
Form SCHEDULE 13G Dianthus Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
August 13, 2026 4:06 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Aug 10 Filed by: McGeorge Anne
August 11, 2026 5:15 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Aug 10 Filed by: Read Simon
August 11, 2026 5:10 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Aug 07 Filed by: Veness Adam M
August 11, 2026 5:09 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Veness Adam M
August 10, 2026 4:51 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Read Simon
August 10, 2026 4:36 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: McGeorge Anne
August 10, 2026 4:34 PM - SEC Filing
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:08 PM - StreetInsider
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026 4:08 PM - StreetInsider
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:07 PM - StreetInsider
Form 4 Dianthus Therapeutics, For: Aug 07 Filed by: Garcia Marino
August 7, 2026 6:31 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Garcia Marino
August 7, 2026 4:38 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Veness Adam M
August 7, 2026 4:38 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Garcia Marino
August 7, 2026 4:20 PM - SEC Filing
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: T. Rowe Price Investment Management, Inc.
August 7, 2026 2:28 PM - SEC Filing
Form SCHEDULE 13G Dianthus Therapeutics, Filed by: T. Rowe Price Investment Management, Inc.
August 7, 2026 2:23 PM - SEC Filing
Dianthus Therapeutics (DNTH) PT Raised to $128 at Truist Securities
August 6, 2026 7:21 AM - StreetInsider
Dianthus Therapeutics (DNTH) PT Raised to $158 at H.C. Wainwright
August 6, 2026 6:54 AM - StreetInsider
Dianthus Therapeutics (DNTH) PT Raised to $131 at Raymond James
August 5, 2026 6:39 AM - StreetInsider
Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c
August 4, 2026 5:17 PM - StreetInsider
Form 10-Q Dianthus Therapeutics, For: Jun 30
August 4, 2026 4:08 PM - SEC Filing
Form 8-K Dianthus Therapeutics, For: Aug 04
August 4, 2026 4:06 PM - SEC Filing
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
August 4, 2026 4:01 PM - Globe NewsWire
Dianthus Therapeutics unveils new bifunctional fusion protein DNTH312
August 4, 2026 7:02 AM - StreetInsider
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 4, 2026 7:00 AM - Globe NewsWire
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 3, 2026 6:00 PM - Globe NewsWire
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: BlackRock, Inc.
July 28, 2026 4:46 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Jul 09 Filed by: Savitz Ryan
July 13, 2026 5:00 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
July 9, 2026 4:27 PM - SEC Filing
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026 4:01 PM - Globe NewsWire
Dianthus starts Phase 3 trial of claseprubart in myasthenia gravis
June 29, 2026 7:01 AM - StreetInsider
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
June 29, 2026 7:00 AM - Globe NewsWire
Form 4 Dianthus Therapeutics, For: Jun 17 Filed by: Veness Adam M
June 18, 2026 4:30 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Veness Adam M
June 17, 2026 4:33 PM - SEC Filing
Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'
June 12, 2026 2:53 PM - StreetInsider
Form 8-K Dianthus Therapeutics, For: Jun 12
June 12, 2026 7:01 AM - SEC Filing
Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
June 10, 2026 4:10 PM - StreetInsider
Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies
June 10, 2026 3:52 PM - StreetInsider
TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'
June 10, 2026 1:37 PM - StreetInsider
Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
June 10, 2026 1:01 PM - StreetInsider
Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'
June 10, 2026 10:40 AM - StreetInsider
Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
June 10, 2026 10:38 AM - StreetInsider
Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel
June 10, 2026 7:21 AM - StreetInsider
Full Article List
